MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEXTM inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history

Inhalation technology and neurology and device delivery systems

Map pharmaceuticals operates in the Pharmaceutical manufacturing industry.

Map pharmaceuticals's revenue is $55.50m

Map pharmaceuticals has 51 - 200 employees.